Search
Citations & References (7)
Invitrogen™
Vybrant™ Cell Metabolic Assay Kit, with C12-resazurin
In the Vybrant™ Cell Metabolic Assay Kit, nonfluorescent C12-resazurin is reduced to fluorescent C12-resorufin by viable cells; the resulting signalRead more
| Catalog Number | Quantity |
|---|---|
| V23110 | 1 kit |
Catalog number V23110
Price (CNY)
5,445.00
1 kit
Quantity:
1 kit
Price (CNY)
5,445.00
1 kit
In the Vybrant™ Cell Metabolic Assay Kit, nonfluorescent C12-resazurin is reduced to fluorescent C12-resorufin by viable cells; the resulting signal is proportional to the number of cells present. C12-resazurin has better cellular retention than alamarBlue™ dye and can be multiplexed with viability indicators and other biomarkers
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Detection MethodFluorescence
Dye TypeResorufin
FormatTube(s), 96-well plate
Quantity1 kit
Shipping ConditionRoom Temperature
For Use With (Application)Cell Metabolic Assay
For Use With (Equipment)Flow Cytometer, Microplate Reader
Product LineVybrant
Product TypeDye
Unit Size1 kit
Contents & Storage
Store in freezer -5°C to -30°C and protect from light.
Frequently asked questions (FAQs)
How do alamarBlue reagent and PrestoBlue reagent differ from resazurin and C12-resazurin?
What is the absorbance/emission of the reaction product from the Vybrant Cell Metabolic Assay Kit?
Citations & References (7)
Citations & References
Abstract
Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus.
Journal:J Bacteriol
PubMed ID:22843840
The skin represents an important barrier for pathogens and is known to produce fatty acids that are toxic toward gram-positive bacteria. A screen of fatty acids as growth inhibitors of Staphylococcus aureus revealed structure-specific antibacterial activity. Fatty acids like oleate (18:1?9) were nontoxic, whereas palmitoleate (16:1?9) was a potent growth
Perturbational profiling of nanomaterial biologic activity.
Journal:Proc Natl Acad Sci U S A
PubMed ID:18492802
'Our understanding of the biologic effects (including toxicity) of nanomaterials is incomplete. In vivo animal studies remain the gold standard; however, widespread testing remains impractical, and the development of in vitro assays that correlate with in vivo activity has proven challenging. Here, we demonstrate the feasibility of analyzing in vitro
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
Journal:Cancer Res
PubMed ID:18922911
'Multivalent antibodies, either monospecific or bispecific, may improve the efficacy of current therapeutic interventions involving a single monoclonal antibody (mAb). We have applied the Dock-and-Lock (DNL) method, a new platform technology for the site-specific and covalent assembly of modular components into stably tethered complexes of defined composition, to prepare a
Preclinical studies on targeted delivery of multiple IFNa2b to HLA-DR in diverse hematologic cancers.
Journal:Blood
PubMed ID:21680794
The short circulating half-life and side effects of IFNa affect its dosing schedule and efficacy. Fusion of IFNa to a tumor-targeting mAb (mAb-IFNa) can enhance potency because of increased tumor localization and improved pharmacokinetics. We used the Dock-and-Lock method to generate C2-2b-2b, a mAb-IFNa comprising tetrameric IFNa2b site-specifically linked to
Hypothermia reduces secretion of vascular endothelial growth factor by cultured retinal pigment epithelial cells.
Journal:Br J Ophthalmol
PubMed ID:20805126
Visual loss in age-related macular degeneration usually develops secondary to choroidal neovascularisation. Vascular endothelial growth factor (VEGF) is a critical regulator of retinal angiogenesis and vascular permeability, especially in hypoxic conditions. We hypothesise that hypothermia may reduce the retinal pigment epithelium (RPE) metabolism and, consequently, the levels of VEGF secretion